Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
Teva Prepared to Fight Charges in Generics Probe If Talks Fail - Bloomberg
Teva Pharmaceutical Stock Could Double | Barron's
Declining sales of blockbuster drug drag Teva revenue lower - MarketWatch
Why Teva Pharmaceutical Is Substantially More (NYSE:TEVA) | Seeking Alpha
Teva agrees to buy Allergan's generics distribution unit
A determined FDA takes down Teva's blockbuster | Evaluate
Teva bullish ahead of 2-step biosimilar attack on AbbVie's blockbuster Humira
Cramer: Avoid This Drug Stock
Teva Pharmaceutical Industries Ltd. | BioWorld
Teva, the world's largest generic drugmaker, is cutting 14,000 workers - Los Angeles Times
Roche's Ocrevus achieves blockbuster status - Pharmaceutical Technology
Teva's Blockbuster Drug Takes Another Generic Blow | Ctech
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
TEVA stock on watch after EU approval for biosimilar to Roche's Lucentis (NYSE:TEVA) | Seeking Alpha
In opioid case, NY wants to probe Teva's control of Teva USA
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters
Generic-drug maker Teva steals market share from Big Pharma - Aug. 5, 2009
Sandoz and Teva invalidate blockbuster apixaban patent and SPC - JUVE Patent
Teva to cut 14,000 jobs | Business | Chemistry World
Teva banks on blockbuster Austedo sales as COVID-19, Copaxone generics take their toll | Fierce Pharma
Teva files potential blockbuster migraine drug for FDA approval
Teva seeks blockbuster drug to succeed Copaxone - Globes
Teva Pharmaceutical Stock: Gem Among Generic Pharma Companies (NYSE:TEVA) | Seeking Alpha
